Storage and Distribution of Cellular Therapy Products Autologous Service Provision

CPV: Blood analysis services

Procedure method

Award procedure without prior publication of a call for competition

Legal basis

CELEX · 32014L0024 Public Contracts Regulations 2015 (Directive 2014/24/EU)

Procurement category

Services

Notice status

Awarded without competition

Procurement threshold

Unspecified in notice

Regulatory regime

Standard

Commercial structure

Stand-alone contract (no framework)

Competition type

Direct award (no call for competition)

GPA / WTO covered

Yes (GPA)

Recurring procurement

Unspecified in notice

First published

19 Aug 2025, 14:56 BST

Last source update

19 Aug 2025, 14:56 BST

Authority reference

C378402

FTS notice number

2025/S 000-049876

Classification (CPV)

Blood analysis services

Delivery area

East of England (UKH1)

Official registry OCID

ocds-h6vhtk-058aa1 Find a Tender

Why no open competition

The procurement falls outside the scope of application of the directive

Published justification

This is a Provider Selection Regime (PSR) intention to award notice. The awarding of this contract is subject to the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015 do not apply to this award. The standstill period begins on the day after the publication of this notice. Representations by providers must be made to decision makers by [Add date]. This contract has not yet formally been awarded; this notice serves as an intention to award under the PSR'

Publisher note: This is a Provider Selection Regime (PSR) intention to award notice. The awarding of this contract is subject to the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015 do not apply to this award. The standstill period begins on the day after the publication of this notice. Representations by providers must be made to the relevant authority by [Add date]. This contract has not yet formally been awarded; this notice serves as an intention to award under the PSR.<br/><br/>Communication can be directed to [email protected]<br/><br/>The award decision makers include the Business Manager, Contracts Manager, Procurement Manager, and representation from the Operational teams.<br/>There are no declared conflicts or potential conflicts of interest of individuals making the decision.<br/><br/>1) Quality and Innovation<br/>NHS Blood and Transplant (NHSBT) has a well-established reputation for delivering services that meet international standards, including support for JACIE-accredited centres. Their expertise in specialist techniques such as CD34+ cell selection, red blood cell depletion, and viability testing contributes directly to improving clinical safety and precision. The service is underpinned by strong quality assurance processes and full traceability, ensuring that patients benefit from safe, reliable and compliant stem cell processing.<br/><br/>2) Value<br/>NHSBT provides a competitively priced service which includes cryopreservation, storage, and a comprehensive suite of testing. Their pricing model offers transparency and good value for money, with bundled services helping to reduce administrative burden and streamline processes. The inclusion of additional services such as donor testing and pre/post-processing enumeration adds further value without extra cost, supporting both operational efficiency and affordability.<br/><br/>3) Integration, Collaboration and Service Sustainability<br/>The service is well aligned with the needs of both NNUH and James Paget University Hospital, with NHSBT already working in partnership with multiple NHS Trusts. Their ability to integrate into existing care pathways and respond flexibly to clinical demands will make them a reliable supplier. The long-term viability of the service will be supported by robust infrastructure, shared systems, and a commitment to continuity of care across the Norfolk and Waveney System. <br/><br/>4) Improving Access, Reducing Health Inequalities and Facilitating Choice<br/>Faster processing and testing times mean patients can access treatment more quickly, which is particularly important in time-sensitive transplant cases. NHSBT’s national infrastructure supports equitable access for patients at the NNUH, helping to reduce health inequalities across the Norfolk and Waveney area - in particular for patients from more remote or underserved areas. This in turn increases patient choice and ensures fairer access to specialist treatment.<br/><br/>5) Social Value<br/>NHSBT delivers strong social value through investment in training, development, and local workforce support. They are actively involved in delivering against NHS sustainability goals, including reducing waste and supporting lower-carbon logistics. Their ethical sourcing policies and commitment to workforce wellbeing also contribute positively to the wider objectives of the NNUH and the NHS as a whole.

• NHS BLOOD AND TRANSPLANT (NHSBT)Awarded supplier972779 500 North Bristol Park, Filton, Bristol, Bristol, UK, BS34 7QHContact phoneShow contact details

No document links were published on the notice.